| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Overview of microbicides for the prevention of human immunodeficiency virus
DOI: 10.1016/j.bpobgyn.2012.01.010
Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmi...
|
Salim S. Abdool Karim,
Cheryl Baxter
|
Full-length article
(In Press Uncorrected Proof)
|
23 February 2012 |
|
Screening for gynaecological cancers – Answers to multiple choice questions for vol. 26, no. 2
DOI: 10.1016/j.bpobgyn.2012.01.008
|
|
Miscellaneous
(In Press Uncorrected Proof)
|
13 February 2012 |
|
Fertility-preserving surgical procedures, techniques
DOI: 10.1016/j.bpobgyn.2012.01.009
As a result of the trend toward late childbearing, fertility preservation has become a major issue in young women with gynaecological cancer. Fertility-sparing treatments have been successfully attemp...
|
A. Martinez,
M. Poilblanc,
G. Ferron,
M. De Cuypere,
E. Jouve,
D. Querleu
et al.
|
Full-length article
(In Press Uncorrected Proof)
|
13 February 2012 |
|
Contraception and pregnancy in microbicide trials
DOI: 10.1016/j.bpobgyn.2012.01.005
The distinctive feature of the human immunodeficiency virus (HIV) epidemic in Sub-Saharan Africa is the burden on women, in particular young women of reproductive age. Consequently, most late-phase ef...
|
Sengeziwe Sibeko,
Gabriel Cohen,
Jagidesa Moodley
|
Full-length article
(In Press Uncorrected Proof)
|
06 February 2012 |
|
Empowering women in human immunodeficiency virus prevention
DOI: 10.1016/j.bpobgyn.2012.01.006
Women comprise one-half of people infected with the human immunodeficiency virus in the world, and about 70% of them live in sub-Saharan Africa. Advancing, untreated HIV disease in women has resulted ...
|
Quarraisha Abdool Karim,
Hilton Humphries,
Zena Stein
|
Full-length article
(In Press Corrected Proof)
|
03 February 2012 |
|
Screening for gynaecological cancers – Multiple choice questions for vol. 26, no. 2
DOI: 10.1016/j.bpobgyn.2012.01.007
|
|
Miscellaneous
(In Press Uncorrected Proof)
|
30 January 2012 |
|
Gynaecological cancer in pregnancy
DOI: 10.1016/j.bpobgyn.2011.12.009
Cancer in pregnancy, fortunately, is uncommon. This is even more so for gynaecological cancer. Fertility preservation in gynaecological cancer is already a difficult issue, as the common gynaecologica...
|
Arunachalam Ilancheran,
Jeffrey Low,
Joseph S. Ng
|
Full-length article
(In Press Corrected Proof)
|
25 January 2012 |
|
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides
DOI: 10.1016/j.bpobgyn.2012.01.004
The development of safe topical microbicides that effectively prevent human immunodeficiency virus (HIV) infection is a major goal in curbing the human immunodeficiency virus pandemic. A number of pas...
|
Jessica L. Adams,
Angela D.M. Kashuba
|
Full-length article
(In Press Corrected Proof)
|
25 January 2012 |
|
Foreword
DOI: 10.1016/j.bpobgyn.2012.01.003
Women in Western societies are progressively delaying child bearing until their mid- to late- thirties, thereby increasing the possibility of developing a gynaecological malignancy before completing t...
|
Neville F. Hacker
|
Editorial
(In Press Corrected Proof)
|
24 January 2012 |
|
Recent advances in oocyte and ovarian tissue cryopreservation and transplantation
DOI: 10.1016/j.bpobgyn.2012.01.001
Options for preserving fertility in women include well-established methods such as fertility-sparing surgery, shielding to reduce radiation damage to reproductive organs, and emergency in-vitro fertil...
|
Kenny A. Rodriguez-Wallberg,
Kutluk Oktay
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
Malignant ovarian germ-cell tumours
DOI: 10.1016/j.bpobgyn.2012.01.002
Malignant ovarian germ-cell tumours account for about 5% of all ovarian malignancies and typically present in the teenage years. They are almost always unilateral and are exquisitely chemosensitive. A...
|
Jeffrey J.H. Low,
Arunachalam Ilancheran,
Joseph S. Ng
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
Borderline ovarian tumours
DOI: 10.1016/j.bpobgyn.2011.12.006
Borderline ovarian tumours account for 10–20% of all epithelial ovarian cancer. Historically, standard primary surgery has included borderline ovarian tumours, omentectomy, peritoneal washing and mult...
|
Claes Göran Tropé,
Janne Kaern,
Ben Davidson
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
Fertility-sparing treatment: Endometrial cancer
DOI: 10.1016/j.bpobgyn.2011.12.007
Endometrial carcinoma is the most common gynaecological malignancy in the Western world. The standard management of endometrial carcinoma is total hysterectomy and bilateral salpingo-oophorectomy with...
|
Vivek Arora,
Michael A. Quinn
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
Statistical and methodological issues in microbicide trial design
DOI: 10.1016/j.bpobgyn.2011.12.008
Microbicide trials aim to measure the effect of a microbicide in reducing the risk of acquiring human immunodeficiency virus. Such trials present a number of challenging issues from design and conduct...
|
Angela M. Crook,
Andrew J. Nunn
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
Fertility preservation in gestational trophoblastic disease
DOI: 10.1016/j.bpobgyn.2011.11.009
Most women with gestational trophoblastic disease are of reproductive age. Because the disease is readily treatable with favourable prognosis, fertility becomes an important issue. Hydatidiform mole i...
|
K.Y. Tse,
Hextan Y.S. Ngan
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
Fertility preservation in gynaecological cancer: Epithelial ovarian cancer
DOI: 10.1016/j.bpobgyn.2011.12.005
The incidence of epithelial ovarian cancer in women aged 40 years and younger is 3–17%. The management of these women is challenging and requires balancing the need to treat epithelial ovarian cancer ...
|
Joseph S. Ng,
Jeffrey J.H. Low,
A. Ilancheran
|
Full-length article
(In Press Corrected Proof)
|
20 January 2012 |
|
Chemotherapy and fertility
DOI: 10.1016/j.bpobgyn.2011.11.008
The overall increase in cancer prevalence and the significant increase in long-term survival have generated worldwide interest in preserving fertility in young women exposed to gonadotoxic chemo- and ...
|
Zeev Blumenfeld
|
Full-length article
(In Press Corrected Proof)
|
20 January 2012 |
|
Cervical cancer
DOI: 10.1016/j.bpobgyn.2011.12.004
Standard treatment for invasive cervical cancer involves either radical surgery or radiotherapy. Childbearing is therefore impossible after either of these treatments. A fertility-sparing option, howe...
|
John H. Shepherd
|
Full-length article
(In Press Corrected Proof)
|
20 January 2012 |
|
Screening for gynaecological cancers
DOI: 10.1016/j.bpobgyn.2011.12.003
This edition of Best Practice & Research, Clinical Obstetrics and Gynaecology focuses on Screening for Gynaecological Cancers and the evidence that it either prevents disease or enables early dete...
|
Lynette Denny
|
Editorial
(In Press Corrected Proof)
|
09 January 2012 |
|
Breast cancer screening in developing countries
DOI: 10.1016/j.bpobgyn.2011.11.007
Diagnosing breast cancer early and efficiently is a critical component of any strategy aimed at decreasing breast cancer mortality in developing countries. In this chapter, I evaluate the evidence beh...
|
Eugenio Panieri
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
Haematological Disorders in Pregnancy: Answers to Multiple Choice Questions for Vol. 26, No. 1
DOI: 10.1016/j.bpobgyn.2011.12.002
|
|
Miscellaneous
(In Press Uncorrected Proof)
|
16 December 2011 |
|
Screening for ovarian cancer in the general population
DOI: 10.1016/j.bpobgyn.2011.11.006
Advances in screening and early detection of ovarian cancer over the past decade have included novel interpretation of serum CA125, discovery of human epididymis protein 4, which has the potential to ...
|
Aleksandra Gentry-Maharaj,
Usha Menon
|
Full-length article
(In Press Corrected Proof)
|
12 December 2011 |
|
Screening and follow up of vulval skin disorders
DOI: 10.1016/j.bpobgyn.2011.11.005
Vulval squamous cell carcinoma is relatively rare; however, up to 20% of women have significant vulval symptoms during their lifetime. Formal screening programmes for vulval disease have not been esta...
|
Lois J. Eva
|
Full-length article
(In Press Corrected Proof)
|
05 December 2011 |
|
Alternative approaches to cervical cancer screening for developing countries
DOI: 10.1016/j.bpobgyn.2011.11.004
Cervical cancer remains the most common cancer among women living in developing countries, largely because of the failure either to initiate or sustain effective cervical-cancer screening programmes. ...
|
Thomas C. Wright,
Louise Kuhn
|
Full-length article
(In Press Uncorrected Proof)
|
02 December 2011 |
|
Human papillomavirus deoxyribonucleic acid testing in developed countries
DOI: 10.1016/j.bpobgyn.2011.11.003
Cervical cancer has been largely eliminated in developed countries with the implementation of cytology-based screening programmes that depend on a call–recall system, followed by colposcopy and biopsy...
|
Neerja Bhatla,
Shilpa Singla,
Divya Awasthi
|
Full-length article
(In Press Corrected Proof)
|
02 December 2011 |
|
Screening for gynaecologic cancers in genetically predisposed women
DOI: 10.1016/j.bpobgyn.2011.11.002
Hereditary breast and ovarian cancer syndrome and hereditary non-polyposis colon cancer syndrome are the two most important syndromes responsible for inherited cancers in gynaecology. Genetic testing ...
|
Greta Dreyer
|
Full-length article
(In Press Corrected Proof)
|
28 November 2011 |
|
New technologies for cervical cancer screening
DOI: 10.1016/j.bpobgyn.2011.11.001
New technologies for cervical cancer screening seek to provide an accurate, efficient and cost-effective way of identifying women at risk for cervical cancer. Current screening uses human papilloma vi...
|
Alaina J. Brown,
Cornelia L. Trimble
|
Full-length article
(In Press Corrected Proof)
|
15 November 2011 |
|
Health economics of screening for gynaecological cancers
DOI: 10.1016/j.bpobgyn.2011.10.013
In this chapter, we summarise findings from recent cost-effectiveness analyses of screening for cervical cancer and ovarian cancer. We begin with a brief summary of key issues that affect the cost-eff...
|
Shalini Kulasingam,
Laura Havrilesky
|
Full-length article
(In Press Corrected Proof)
|
15 November 2011 |
|
Visual inspection methods for cervical cancer prevention
DOI: 10.1016/j.bpobgyn.2011.08.003
The need for simple, cost-effective screening approaches for cervical cancer prevention in low-resource countries has led to the evaluation of visual screening with 3–5% acetic acid. The low reproduci...
|
Rengaswamy Sankaranarayanan,
Ashrafun Nessa,
Pulikattil Okkuru Esmy,
Jean-Marie Dangou
|
Review article
(In Press Corrected Proof)
|
31 October 2011 |
|
Cytological screening for cervical cancer prevention
DOI: 10.1016/j.bpobgyn.2011.08.001
Historically, the incidence and mortality of cervical cancer has declined in countries that have instituted and sustained mass-organised cytology-based screening programmes. These programmes, however,...
|
Lynette Denny
|
Review article
(In Press Corrected Proof)
|
31 October 2011 |
|
Screening for uterine tumours
DOI: 10.1016/j.bpobgyn.2011.08.002
The most prevalent uterine tumours are leiomyomas, which are benign and have a prevalence of about 50% at menopause. The incidence of endometrial cancer and uterine sarcomas is about 25 per 100,000 an...
|
Thierry Van den Bosch,
An Coosemans,
Memli Morina,
Dirk Timmerman,
Frederic Amant
et al.
|
Review article
(In Press Corrected Proof)
|
28 October 2011 |